GO
Loading...

Medicine

More

  • Accelerating Ebola vaccine     Thursday, 4 Sep 2014 | 3:25 PM ET

    CNBC's Meg Tirrell speaks to Johnson & Johnson chairman, Joaquin Duato, about J&J's partnership with the National Institutes of Health to fast track its Ebola vaccine program to begin human testing by early 2015.

  • Diabetes monitoring goes mobile     Thursday, 4 Sep 2014 | 2:38 PM ET

    Discussing the new ways to monitor glucose for people with diabetes, and competition in the space, with Terry Gregg, DexCom CEO. Gregg says his business is in conversations with Apple and Samsung in regards to partnering on wearables.

  • Sept 3- U.S. drugmaker AbbVie Inc and Calico, a new company set up by Google Inc to cure diseases of aging, will each invest $250 million to help create Calico research facilities and collaborate on discovery and development of new medicines.

  • AbbVie, Calico forge deal against age-related diseases Wednesday, 3 Sep 2014 | 1:03 PM ET

    Sept 3- U.S. drugmaker AbbVie Inc and Calico, a new company set up by Google Inc to cure diseases of aging, will each invest $250 million to help create Calico research facilities and collaborate on discovery and development of new medicines.

  • Sept 3- Chimerix Inc said its lead experimental drug showed promise against the deadly Ebola virus in laboratory testing at the U.S. Centers for Disease Control and Prevention and the National Institutes of Health.

  • Chimerix says antiviral shows promise against Ebola Wednesday, 3 Sep 2014 | 8:21 AM ET

    Sept 3- Chimerix Inc said its experimental drug showed promise against the deadly Ebola virus in laboratory testing at the U.S. Centers for Disease Control and Prevention and the National Institutes of Health.

  • PARIS, Sept 3- French drugmaker Sanofi, developing the first vaccine against dengue fever, said its product reduced disease cases by 60.8 percent in a large final clinical trial. Sanofi has invested more than 1.3 billion euros in the project, undertaking two decades of research on the world's fastest-growing tropical disease.

  • Sept 2- The U.S. Department of Health and Human Services said on Tuesday a federal contract worth up to $42.3 million would help accelerate testing of an experimental Ebola virus treatment that is being developed by privately held Mapp Biopharmaceutical Inc..

  • Biotech's $10 billion opportunity     Tuesday, 2 Sep 2014 | 1:34 PM ET

    CNBC's Meg Tirrell reports experimental cholesterol medicines by Amgen and Regeneron represent a potential $10 billion opportunity pending FDA approval in the U.S.

  • Race for cholesterol drugs     Tuesday, 2 Sep 2014 | 8:17 AM ET

    A new class of drugs which aim to lower levels of LDL are being pursued by multiple pharma companies and it could be a $10 billion market. Leonard Schleifer, Regeneron CEO, discusses what is known about bad cholesterol, and competition in the space.

  • BARCELONA, Sept 1- A nerve stimulation device from Cyberonics improved cardiac function in heart failure patients in a small clinical trial, in contrast to an unsuccessful study backed by Boston Scientific.

  • *Sanofi, Regeneron vying with drugs from Amgen and Pfizer. BARCELONA, Aug 31- An experimental cholesterol-lowering drug from Sanofi and Regeneron Pharmaceuticals roughly halved the number of heart attacks and strokes in a clinical trial, researchers reported on Sunday.

  • The success is therefore a "monumental achievement," virologist Thomas Geisbert of the University of Texas Medical Branch wrote in a commentary on the paper, published online in Nature.

  • Aug 29- BioCryst Pharmaceuticals Inc said it expects to initiate a study within weeks to test its antiviral in primates for use against Ebola infections. This $2.4 million National Institute of Allergy and Infectious Diseases funding is in addition to the $22 million contract awarded to BioCryst by the agency last September.

  • *AstraZeneca shares up 2 percent. LONDON, Aug 29- Hopes for AstraZeneca's promising cancer drug pipeline were boosted on Friday by news the company had moved its immuno-oncology medicine MEDI-4736 into a mid-stage study in colorectal cancer.

  • CHICAGO, Aug 28- Genetic studies of some of the earliest Ebola cases in Sierra Leone reveal more than 300 genetic changes in the virus as it leapt from person to person, changes that could blunt the effectiveness of diagnostic tests and experimental treatments now in development, researchers said on Thursday.

  • Ebola response roadmap     Thursday, 28 Aug 2014 | 1:52 PM ET

    GlaxoSmithKline is to begin human testing of an experimental Ebola vaccine. CNBC's Meg Tirrell reports the World Health Organization has released a response roadmap with the goal of stopping the spread of Ebola in 6 to 9 months.

  • GENEVA/ LAGOS Aug 28- The Ebola epidemic in West Africa could infect more than 20,000 people, the U.N. health agency said on Thursday, warning that an international effort costing almost half a billion dollars is needed to overcome the outbreak.

  • Aug 28- OncoMed Pharmaceuticals Inc said the U.S. Food and Drug Administration lifted a partial hold on patient enrolments for three trials testing its experimental cancer drug, vantictumab.

  • Human trials of Ebola vaccine to start next week Thursday, 28 Aug 2014 | 8:09 AM ET
    Medicins Sans Frontieres health workers at an isolation camp in Liberia during the visit of the UN Ebola systems coordinator, Aug. 23, 2014.

    The trials will start at the NIH in Maryland. A vaccine is "the first step in a long process" to control Ebola, Dr. Anthony Fauci says. NBC reports.